Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary
malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors …

Pulmonary sarcomatoid carcinoma (PSC) is a heterogeneous category of primary lung
cancer accounting from 0.3% to 3% of all primary lung malignancies. According to the most …

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer with poor
prognosis. Here, we perform multi-omics analysis of 56 PSC samples, 14 of which are …

Background Previous studies have suggested that patients with pulmonary sarcomatoid
carcinoma (PSC) may benefit from immune checkpoint inhibitors (ICIs); however, relevant …

Pulmonary sarcomatoid carcinoma (PSC) contains carcinomatous component (CaC) and
sarcomatous component (SaC). Herein, we explored the genomic origin and intratumor …

Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non‐small‐cell lung cancer
(NSCLC) that is currently managed under guidelines used for conventional NSCLC and has …

Background Cholangiocarcinoma (CCA), which consists of intrahepatic CCA (iCCA),
perihilar CCA (pCCA), and distal CCA (dCCA), is an aggressive malignancy worldwide …

Objectives Pulmonary sarcomatoid carcinoma (PSC) is a rarely occurring variant of non-
small cell lung cancer with sarcoma-like features. Compared with traditional non-small cell …

Simple Summary Lung cancer is the world leading cause of cancer death. Therefore, a
better understanding of the disease is needed to improve patient survival. In this work, we …

Undifferentiated sarcomatoid carcinoma (USC) of the pancreas is a rare but especially
aggressive variant of pancreatic ductal adenocarcinoma (PDAC), composed of at least 80 …